medigraphic.com
ISSN 1729-519X (Print)

2016, Number 5

<< Back Next >>

Revista Habanera de Ciencias Médicas 2016; 15 (5)

New perspectives in the pharmacological treatment of Hepatitis C

Gómez-Aparicio S, Vicente EJ, Alegre GF

Language: Spanish
References: 22
Page: 724-743
PDF size: 166.45 Kb.


ABSTRACT

Introduction: The infection by the Hepatitis C virus (HCV) is one of the most common causes of liver's disease worldwide. Approximately between 60-80% of infected people, infection becomes chronic, and can lead in the long-term to the development of other liver's diseases such as cirrhosis and the hepatocellular carcinoma. Treatment of HCV has progressed enormously in the last decade, concluding with the development of Direct-acting Antiviral Agents (DAA), which has achieved cure rates over 90%.
Objective: To know the different available treatments options as well as which will be available in a near future.
Materials and methods: Several systematic searches were made in the PubMed database; in the articles from the "liver meeting" congress of AASLD (American Association for the Study of Liver Diseases) in November 2014 and in the EASL (European Association for the Study of Liver) guide.
Development: The arrivals of new drugs with new therapeutic strategies have made this therapy more complex, and for that reason it is necessary to have knowledge of these drugs and their possible combinations.
Conclusions: The excellent results of the therapy with AAD have made a huge change in therapeutic recommendations, making possible shorter therapies, better tolerated by patients and safer for health.


REFERENCES

  1. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308.

  2. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013 Jul;19(7):850-8.

  3. Chan J. Hepatitis C. Dis Mon. 2014 May;60(5):201-12.

  4. Antiviral treatments for hepatitis C infection. Br J Clin Pharmacol. 2013 Apr;75(4):931-43.

  5. Kim DY, Ahn SH, Han KH. Emerging Therapies for Hepatitis C. Gut Liver. 2014 Sep;8(5):471-9.

  6. Belousova V, Abd-Rabou AA, Mousa SA. Recent advances and future directions in the management of hepatitis C infections. Pharmacol Ther. 2014 Sep 6.

  7. ddLemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med. 2014 Jun;20(6):315-21.

  8. Jaroszewicz J, Flisiak R, Dusheiko G. A pill for HCV - myth or foreseeable future? Liver Int. 2014 Jan;34(1):6-11.

  9. Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014 May;109(5):628-35.

  10. Lim TR, Tan BH, Mutimer DJ. Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. Int J Antimicrob Agents. 2014 Jan;43(1):17-25.

  11. Pawlotsky JM, Aghemo A, Dusheiko G, Forns X, Puoti M, Sarrazin C. EASL Recommendations on Treatment of Hepatitis C -. 2014. EASL 2014.

  12. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014 May;146(5):1176-92.

  13. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014 Feb;34 Suppl 1:69-78.

  14. Pol S, Corouge M. Treatment of hepatitis C: Perspectives. Med Mal Infect. 2014 Aug 27.

  15. Garrison KL, Wang,Y, Brainard DM,.Sajwani K, Mathias A. The Effect of Rifampin on the Pharmacokinetics of Sofosbuvir in Healthy Volunteers. 2014 AASLD - The Liver Meeting . 9-11-2014.

  16. Gerold G, Pietschmann T. The HCV life cycle: in vitro tissue culture systems and therapeutic targets. Dig Dis. 2014;32(5):525-37.

  17. Imran M, Manzoor S, Khattak NM, Khalid M, Ahmed QL, Parvaiz F, et al. Current and future therapies for hepatitis C virus infection: from viral proteins to host targets. Arch Virol. 2014 May;159(5):831-46.

  18. Jimenez GR, Albacete RA, Monje AP, Borrego IY, Morillo VR. [New drugs in the treatment of chronic hepatitis C]. Farm Hosp. 2014 May;38(3):231-47.

  19. Ferenci P. Breakthrougs in Treatment of Chronic Hepatitis C - Time for an Obituary for Peginterferon/Ribavirin? J Infect Dis Ther. 2014.

  20. Lin MV, Gogela NA, Thim M, Pratt DS, Andersson KL, et al. Real World Experience with Sofosbuvir and Simeprevir combination treatment in patients with HCV genotype 1 2014 AASLD - The Liver Meeting . 9-11-2014.

  21. European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol. 2015 Apr 21.

  22. Shahid I, ALMalki WH, Hafeez MH, Hassan S. Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. Crit Rev Microbiol. 2014 Nov 6;1-13.




2020     |     www.medigraphic.com